title: Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes.
abstract: Vascular endothelial growth factor (VEGF) is anti-cytotoxic in podocytes. Moreover, it has been suggested that nephrin, a cell adhesion molecule of the podocyte slit diaphragm, can contribute to antiapoptotic mechanisms in these cells. We therefore investigated whether VEGF signals to reduce apoptosis and the role of nephrin in this survival mechanism. Flow cytometry showed that podocytes with nephrin mutations had a significantly greater proportion of apoptosis. Although VEGF reduced apoptosis in human conditionally immortalized podocytes [wild-type (WT)] by 18.1% of control (P < 0.001), it was unable to do so in nephrin-deficient human conditionally immortalized podocytes. Moreover, Western blotting and immunodetection with an anti-nephrin antibody showed that the phosphorylation of nephrin, compared with serum-starved WTs, was significantly increased (ratio of 3.36 +/- 1.2 to control, P < 0.05) by VEGF treatment and significantly reduced by treatment with a neutralizing VEGF monoclonal antibody (mAb) (ratio of 0.2 +/- 0.09 to control, P < 0.05). The AKT signaling pathway has been implicated in nephrin-mediated inhibition of apoptosis in transfected cells, but the role of this pathway has not previously been shown in podocytes. Surprisingly, exogenous VEGF decreased AKT/PKB phosphorylation in normal podocytes but increased it in nephrin-deficient podocytes. We suggest therefore that both exogenous and endogenous (podocyte derived) VEGF can stimulate the phosphorylation of nephrin and through this action may prevent podocyte apoptosis. However, the involvement of AKT in this survival response in normal human podocytes is not clear.
authors.affiliation: Microvascular Research Laboratories, Department of Physiology, University of Bristol, Preclinical Veterinary School, Southwell St., Bristol BS2 8EJ, UK.
authors.forename: Rebecca R
authors.initials: RR
authors.lastname: Foster
authors.forename: Moin A
authors.initials: MA
authors.lastname: Saleem
authors.forename: Peter W
authors.initials: PW
authors.lastname: Mathieson
authors.forename: David O
authors.initials: DO
authors.lastname: Bates
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Harper
mesh_terms: D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D002460:Cell Line; D040461:Gene Components; D006801:Humans; D007678:Kidney Glomerulus / Q000166:cytology* / Q000502:physiology*; D008565:Membrane Proteins; D009154:Mutation; D010766:Phosphorylation; D011487:Protein Conformation; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D017434:Protein Structure, Tertiary; D011506:Proteins / Q000235:genetics / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
chemical_list: D008565:Membrane Proteins; D011506:Proteins; D011518:Proto-Oncogene Proteins; D042461:Vascular Endothelial Growth Factor A; C113267:nephrin; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt